@article{6339f0c7a41542549124a71e1793d1b5,
title = "Quantitative affinity measurement of small molecule ligand binding to major histocompatibility complex class-I–related protein 1 MR1",
abstract = "The Major Histocompatibility Complex class I–related protein 1 (MR1) presents small molecule metabolites, drugs, and drug-like molecules that are recognized by MR1-reactive T cells. While we have an understanding of how antigens bind to MR1 and upregulate MR1 cell surface expression, a quantitative, cell-free, assessment of MR1 ligand-binding affinity was lacking. Here, we developed a fluorescence polarization–based assay in which fluorescent MR1 ligand was loaded into MR1 protein in vitro and competitively displaced by candidate ligands over a range of concentrations. Using this assay, ligand affinity for MR1 could be differentiated as strong (IC50 < 1 μM), moderate (1 μM < IC50 < 100 μM), and weak (IC50 > 100 μM). We demonstrated a clear correlation between ligand-binding affinity for MR1, the presence of a covalent bond between MR1 and ligand, and the number of salt bridge and hydrogen bonds formed between MR1 and ligand. Using this newly developed fluorescence polarization–based assay to screen for candidate ligands, we identified the dietary molecules vanillin and ethylvanillin as weak bona fide MR1 ligands. Both upregulated MR1 on the surface of C1R.MR1 cells and the crystal structure of a MAIT cell T cell receptor–MR1–ethylvanillin complex revealed that ethylvanillin formed a Schiff base with K43 of MR1 and was buried within the Aʹ-pocket. Collectively, we developed and validated a method to quantitate the binding affinities of ligands for MR1 that will enable an efficient and rapid screening of candidate MR1 ligands.",
keywords = "antigen presentation, fluorescence, Immunology, structural biology",
author = "Wang, {Carl J.H.} and Wael Awad and Ligong Liu and Mak, {Jeffrey Y.W.} and Natacha Veerapen and Illing, {Patricia T.} and Purcell, {Anthony W.} and Eckle, {Sidonia B.G.} and James McCluskey and Besra, {Gurdyal S.} and Fairlie, {David P.} and Jamie Rossjohn and {Le Nours}, J{\'e}r{\^o}me",
note = "Funding Information: We thank the staff at the National Synchrotron for assistance with data collection and at the Monash Macromolecular Crystallization Facility (MMCF). We thank Ms Daphne Ju for technical assistance with the MR1 upregulation assay. We thank Dr Jia Jia Lim and Ms Keshia Kim for their assistance in the development of the MR1 FP competitive binding assay. The crystallography research was undertaken on the MX2 beamline at the Australian Synchrotron, part of ANSTO (45). We thank the Australian Research Council (ARC) (DP220102401 and Centre of Excellence in Advanced Molecular Imaging Grant CE140100011), the NHMRC (SPRF1027369, SPRF1117017, and APP1125493), the Allergy and Immunology Foundation of Australasia (AIFA), and the U.S. National Institute of Health (RO1 Grant AI148407-01A1) for funding. C. J. H. W. methodology; C. J. H. W. W. A. L. L. J. Y. W. M. P. T. I. A. W. P. S. B. G. E. J. M. G. S. B. and D. P. F. investigation; L. L. J. Y. W. M. S. B. G. E. J. M. G. S. B. and D. P. F. resources; C. J. H. W. N. V. J. R. and J. L. N. data curation; C. J. H. W. J. R. and J. L. N. writing–original draft. C. J. H. W. is supported by an Australian Government Research Training Program (RTP) Scholarship. W. A. is supported by an ARC Discovery Early Career Researcher Award (DE220101491). L. L. J. Y. W. M, and D. P. F. were supported by NHMRC Fellowship (1117017) and Investigator Grant (2009551). A. W. P. is supported by an NHMRC Principal Research Fellowship (1137739). J. M. and J. R. (2008616) are supported by NMHRC Leadership Investigator Grants. S. B. G. E. is supported by an NHMRC Emerging Leadership Investigator Award (1196881). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: We thank the staff at the National Synchrotron for assistance with data collection and at the Monash Macromolecular Crystallization Facility (MMCF). We thank Ms Daphne Ju for technical assistance with the MR1 upregulation assay. We thank Dr Jia Jia Lim and Ms Keshia Kim for their assistance in the development of the MR1 FP competitive binding assay. The crystallography research was undertaken on the MX2 beamline at the Australian Synchrotron, part of ANSTO ( 45 ). We thank the Australian Research Council (ARC) (DP220102401 and Centre of Excellence in Advanced Molecular Imaging Grant CE140100011), the NHMRC (SPRF1027369, SPRF1117017, and APP1125493), the Allergy and Immunology Foundation of Australasia (AIFA), and the U.S. National Institute of Health (RO1 Grant AI148407-01A1) for funding. Funding Information: C. J. H. W. is supported by an Australian Government Research Training Program (RTP) Scholarship. W. A. is supported by an ARC Discovery Early Career Researcher Award (DE220101491). L. L., J. Y. W. M, and D. P. F. were supported by NHMRC Fellowship (1117017) and Investigator Grant (2009551). A. W. P. is supported by an NHMRC Principal Research Fellowship (1137739). J. M. and J. R. (2008616) are supported by NMHRC Leadership Investigator Grants. S. B. G. E. is supported by an NHMRC Emerging Leadership Investigator Award (1196881). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = dec,
doi = "10.1016/j.jbc.2022.102714",
language = "English",
volume = "298",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology",
number = "12",
}